USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. Dirk Arnold, M.D., Ph.D., Director of Asklepios Tumorzentrum Hamburg and primary investigator of the GOBLET trial commented, "I have been pleased to observe the strength of the clinical response data for pelareorep in multiple cohorts of the GOBLET gastrointestinal study, especially in pancreatic and anal cancer. mFOLFIRINOX is currently considered the best treatment option for many pancreatic cancer patients. Therefore, the evaluati ...

Demonstrating pelareorep's synergy with modified FOLFIRINOX +/- atezolizumab in pancreatic cancer could expand the number of patients it may benefit SAN DIEGO, and CALGARY, AB, June 20, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, announced the dosing of the first patient in the new GOBLET study cohort evaluating pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with or without atezolizumab (Tecentri ...

USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 19, 2024 /PRNewswire/ -- USA News Group – This year's 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) has now come and gone, but not without increasing hope for cancer patients around the world. This year's ASCO 2024 theme was 'The Art and Science of Cancer Care: From comfort to cure,' with attendees hearing presentations from experts and receiving a wide range of important clinical results for ...

USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. Presented recently at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) presented two abstracts related to their novel immunotherapy, pelareorep, an intravenously delivered immunotherapeutic agent. "The first abstract outlines the design of a new GOBLET PDAC cohort that could significantly expand the potential of the company's pancreatic cancer program," said Dr. Matt C ...

A downtrend has been apparent in Oncolytics Biotech Inc. (ONCY) lately. While the stock has lost 9.3% over the past four weeks, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support. While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about ...

USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 3, 2024 /PRNewswire/ -- USA News Group – Recognized as one of the most lethal cancers, researchers are striving to improve survival rates for pancreatic cancer patients by focusing on earlier detection. According to Johns Hopkins Medicine, up to 80% of patients are diagnosed at advanced stages, which are significantly harder to treat. A new study published in the journal Cell Genomics demonstrates that researchers have ...

USA News Group Commentary VANCOUVER, BC, May 28, 2024 /PRNewswire/ -- USA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years in young adults, according to surgeons at Yale Medicine. As well, there are now alarming reports around the world of rising diagnoses of HIV, which is being linked to higher anal cancer mortality for women. Worldwide, improved access to testing led to a 4.2% increase in HIV diagnoses in the EU and a whopping 120% increase in Montreal, Canad ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, May 24, 2024 /PRNewswire/ -- USA News Group News Commentary – As the 2024 American Society of Clinical Oncology (ASCO) annual meeting approaches, excitement builds over the latest in cancer treatment advancements, particularly in Antibody-Drug Conjugates (ADCs). From May 31 to June 4, industry leaders will unveil new data on late-stage and approved therapies. Recent FDA approvals are also enriching the treatment landscape, offering patients innovati ...

Core Insights - Oncolytics Biotech Inc. presented two abstracts at the 2024 ASCO Annual Meeting, focusing on the potential of pelareorep in treating metastatic pancreatic ductal adenocarcinoma (PDAC) and its immunotherapeutic mechanism [1][2] Group 1: Study Details - The GOBLET study's cohort 5 will evaluate pelareorep combined with modified FOLFIRINOX (mFOLFIRINOX) with and without atezolizumab in newly diagnosed metastatic PDAC patients [1][4] - The study employs a Simon two-stage design, with Stage 1 involving 15 evaluable patients per treatment arm [4][5] - Co-primary endpoints include objective response rate and safety, with secondary endpoints assessing progression-free and overall survival [4][5] Group 2: Funding and Enrollment - The GOBLET cohort is funded by a US$5 million grant from the Pancreatic Cancer Action Network (PanCAN) [2] - Enrollment for this cohort is expected to begin in the current quarter [2] Group 3: Mechanism of Action - Pelareorep stimulates a proinflammatory response, enhancing both innate and adaptive immune responses, which may improve treatment outcomes [2][10] - The second abstract highlights pelareorep's ability to expand tumor-infiltrating lymphocytes (TILs), correlating TIL expansion with tumor response [2][10] Group 4: Clinical Implications - Previous studies indicated that the combination of pelareorep with gemcitabine, nab-paclitaxel, and atezolizumab achieved tumor response rates nearly three times higher than historical results [2] - If the mFOLFIRINOX combination yields similar positive outcomes, a broader range of metastatic PDAC patients may benefit from pelareorep-based therapy [2] Group 5: Future Directions - The GOBLET study aims to further investigate TIL expansion as a potential biomarker for clinical activity in patients treated with pelareorep [2][10] - Oncolytics is advancing towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA [12][13]

Core Insights - The article discusses advancements in pancreatic cancer research and treatment, highlighting the importance of early detection and innovative therapies being developed by various biotech companies [1][2][3]. Group 1: Pancreatic Cancer Statistics and Research - Pancreatic cancer is one of the deadliest cancers, with up to 80% of patients diagnosed at late stages, making early detection crucial [1]. - The American Cancer Society estimates that approximately 66,440 individuals in the USA will be diagnosed with pancreatic cancer in 2024, with about 51,750 expected to die from the disease [1]. Group 2: Oncolytics Biotech Inc. Developments - Oncolytics Biotech's pelareorep has received Fast Track Designation from the FDA for pancreatic cancer treatment and is collaborating with the Global Coalition for Adaptive Research (GCAR) to evaluate its use as a first-line treatment for metastatic pancreatic ductal adenocarcinoma [2][3]. - The company is advancing research on pelareorep combined with modified FOLFIRINOX (mFOLFIRINOX) and Tecentriq, with a new study cohort cleared for patient enrollment [3][5]. Group 3: Other Biotech Companies and Innovations - Candel Therapeutics received FDA orphan drug designation for its CAN-2409 treatment in pancreatic cancer, which combines a specially engineered virus with valacyclovir to enhance immune response against tumors [6][8]. - AstraZeneca's drug Enhertu has received accelerated approval for treatment across multiple HER2-expressing solid tumors, including pancreatic cancer [9][10]. - Merus N.V. announced the FDA's acceptance of a Biologics License Application for zenocutuzumab, targeting NRG1+ pancreatic cancer, which may offer a substantial improvement over existing therapies [10][11]. - Lantern Pharma is collaborating with Oregon Therapeutics to optimize the development of XCE853, a first-in-class drug candidate for various cancers, including drug-resistant pancreatic cancer [12][13].